°£¼¼Æ÷¾Ï : KOL ÀλçÀÌÆ®
Hepatocellular Carcinoma - KOL Insight
»óǰÄÚµå : 1524359
¸®¼­Ä¡»ç : FirstWord Group
¹ßÇàÀÏ : 2024³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 39,950 £Ü 55,019,000
Multi User License (PDF) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. PDF ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

°£¼¼Æ÷¾Ï(HCC) Ä¡·á ȯ°æÀÇ ÁøÀü »óȲ¿¡ ´ëÇØ ºÐ¼®Çϰí ÀÖ½À´Ï´Ù. ÀýÁ¦ ºÒ°¡´ÉÇÑ °£¼¼Æ÷¾ÏÀÇ 1Â÷ Ä¡·á·Î¼­ RocheÀÇ Tecentriq(¾ÆÅ×Á¹¸®ÁÖ¸¿)¿Í Avastin(º£¹Ù½ÃÁÖ¸¿)ÀÇ º´¿ë¿ä¹ýÀÌ °è¼Ó Á¤ÂøÇϰí ÀÖ´Â °Í¿¡ ´ëÇØ ÁÖ¿ä KOLÀÌ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ ¾Æ¹Ù½ºÆ¾ÀÌ ±Ý±âÀΠȯÀÚ¿¡ ´ëÇÑ AstraZenecaÀÇ Imfinzi(´õ¹ß·ç¸¿)¿Í Imjudo(Æ®·¹¸á¸®¹«¸¿)ÀÇ »ç¿ë Áõ°¡ ¹× Bristol Myers SquibbÀÇ Opdivo(´Ïº¼·ç¸¿)¿Í Uervoy(ÀÌÇʸ®¹«¸¿)ÀÇ 1Â÷ Ä¡·á·Î¼­ÀÇ °¡´É¼º, ½Å±Ô Ä¡·áÁ¦ÀÇ »õ·Î¿î ¿ªÇÒ, ÀÓ»ó Áø·á¡¤ÀǾàǰ °³¹ß¿¡ ´ëÇÑ ¿µÇ⠵ ´ëÇØ ÀÌÇØÇÕ´Ï´Ù.

ÀÌ º¸°í¼­¿¡¼­ ´äº¯ÇÏ´Â ÁÖ¿ä Áú¹® :

ÀÌ º¸°í¼­ÀÇ Á¶»ç ´ë»ó ÁÖ¿ä ºê·£µå

  • Tecentriq(¾ÆÅ×Á¹¸®ÁÖ¸¿)
  • Avastin(º£¹Ù½ÃÁÖ¸¿)
  • Imfinzi(´õ¹ß·ç¸¿)
  • Imjudo(Æ®·¹¸á¸®¹«¸¿)
  • Opdivo(´Ïº¼·ç¸¿)
  • Yervoy(ÀÌÇʸ®¹«¸¿)
  • Keytruda(Æèºê·Î¸®ÁÖ¸¿)
  • Tevimbra/Tizveni(tislelizumab)
  • Camrelizumab
  • Rivoceranib
  • Nofazinlimab
  • Loqtorzi(toripalimab)
  • Nexavar(¼Ò¶óÆä´Õ)
  • Lenvima(·»¹ÙƼ´Õ)
  • Stivarga(·¹°í¶óÆä´Õ)
  • Cabometyx(Ä«º¸ÀÜÆ¼´Õ)
  • Cyramza(¶ó¹«½Ã·ç¸¿)
  • Namodenoson
  • Tiragolumab
  • Livmoniplimab
  • Budigalimab
  • Casdozokitug
  • Fostrox
  • Amezalpat

Á¶»ç ´ë»ó ±â¾÷

  • AbbVie
  • Lilly
  • Roche
  • AstraZeneca
  • Merck & Co.
  • Bristol Myers Squibb
  • Jiangsu HengRui Medicine
  • Can-Fite
  • Eisai
  • Bayer
  • Elevar Therapeutics
  • BeiGene
  • Exelixis
  • Ipsen
  • CStone
  • Coherus
  • Junshi Biosciences
  • Ono Pharmaceutical
  • Tempest Therapeutics
  • Medivir
  • 3SBio

¸ñÂ÷

°³¿ä

ÇöÀ硤ÇâÈÄ Ä¡·á ¾Ë°í¸®Áò

Á¶»ç ¸ñÀû

üũÆ÷ÀÎÆ® ÀúÇØÁ¦

Ƽ·Î½ÅŰ³ª¾ÆÁ¦ ÀúÇØÁ¦

VEGFR ÀúÇØÁ¦

±âŸ ÀÛ¿ë±â¼­

ÇâÈÄ Ä¡·á µ¿Çâ

ºÎ·Ï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Explore the evolving landscape of hepatocellular carcinoma (HCC) treatment. Leading KOLs provide insights on the consolidation of Roche's Tecentriq (atezolizumab) plus Avastin (bevacizumab) as the first-line treatment for unresectable HCC, the rising use of AstraZeneca's Imfinzi (durvalumab) plus Imjudo (tremelimumab) for patients contraindicated for Avastin, and the potential of Bristol Myers Squibb's Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment. Gain an understanding of the emerging role of novel therapies and the implications for clinical practice and drug development.

Key questions answered:

Key brands covered in this report:

  • Tecentriq (atezolizumab)
  • Avastin (bevacizumab)
  • Imfinzi (durvalumab)
  • Imjudo (tremelimumab)
  • Opdivo (nivolumab)
  • Yervoy (ipilimumab)
  • Keytruda (pembrolizumab)
  • Tevimbra/Tizveni (tislelizumab)
  • Camrelizumab
  • Rivoceranib
  • Nofazinlimab
  • Loqtorzi (toripalimab)
  • Nexavar (sorafenib)
  • Lenvima (lenvatinib)
  • Stivarga (regorafenib)
  • Cabometyx (cabozantinib)
  • Cyramza (ramucirumab)
  • Namodenoson
  • Tiragolumab
  • Livmoniplimab
  • Budigalimab
  • Casdozokitug
  • Fostrox
  • Amezalpat

Companies:

  • AbbVie
  • Lilly
  • Roche
  • AstraZeneca
  • Merck & Co.
  • Bristol Myers Squibb
  • Jiangsu HengRui Medicine
  • Can-Fite
  • Eisai
  • Bayer
  • Elevar Therapeutics
  • BeiGene
  • Exelixis
  • Ipsen
  • CStone
  • Coherus
  • Junshi Biosciences
  • Ono Pharmaceutical
  • Tempest Therapeutics
  • Medivir
  • 3SBio

Table of Contents

Executive summary

Current and future treatment algorithm

Research objectives

Checkpoint inhibitors

Tyrosine kinase inhibitors

VEGFR inhibitors

Other mechanisms of action

Future treatment trends

Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â